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 Glomerulosclerosis and interstitial  fi brosis 
are characteristic fi ndings of chronic 
 kidney  disease, irrespective of its under-
lying cause. Th ese processes are charac-
terized by the accumulation of collagens, 
 laminins, fi bronectin, and key molecules 
in  fi brosis, including transforming growth 
 factor-  (TGF-  ) and connective tissue 
growth factor (CTGF). 1 TGF-  is up-
regulated in renal diseases including dia-
betic nephropathy and focal segmental 
glomerulosclerosis, where it is associated 
with cell proliferation,  diff erentiation (epi-
thelial – mesenchymal transition), and the 
remodeling of the extracellular  matrix. 
Many of these profi brotic actions of TGF-  
are mediated by CTGF downstream. 
Th e promoter of CTGF contains several 
Smad-binding domains, which can be 
activated by TGF-  . 1 Like TGF-  , CTGF 
is upregulated in diverse nephropathies 
and directly stimulates the synthesis of 
collagens in several renal cell types. 1 
 Ren and colleagues 2 (this issue) postu-
late a role for sphingosine kinase-1 in the 
regulation of CTGF expression initiated 
by TGF-  in the podocyte cells of the 
 kidney glomerulus. Sphingosine kinases 
(SKs) act on sphingolipids, which are key 
components of all eukaryotic cell mem-
branes; they protect the cell surface by 
forming the outer leaflet of the lipid 
bilayer. 3 The action of the SK enzymes 
produces the lipid mediator sphingosine-1-
phosphate. Sphingosine-1-phosphate has 
diverse actions, acting not only as an intra-
cellular messenger that changes cell turn-
over, but also as an extracellular ligand 
that can bind to sphingosine-1-phosphate 
receptors on neighboring cells. Activation 
of these G protein–coupled receptors leads 
to alterations in cell migration and diff er-
entiation, therefore modulating processes 
such as angiogenesis and the branching 
of the ureteric bud that are affected 
by cell motility. 3,4 There are two main 
 isoforms of SK with highly contrasting 
biological roles: SK-1, which promotes the 
survival of cells, and SK-2, which has been 
implicated in cell death through apopto-
sis. 3 In the kidney, both SK enzymes are 
expressed throughout development, 
predominantly in the metanephric mes-
enchyme, with higher levels of expression 
found in mature kidneys. 3,4 
 Podocytes are specialized epithelia with 
foot processes attached to the glomerular 
basement membrane. Neighboring proc-
esses are separated by specialized tight 
junctions called slit diaphragms, which 
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 Renal  fibrosis contributes to glomerulosclerosis and tubulointerstitial 
damage in chronic kidney disease. A well-established pathway 
implicated in the progression of fibrosis is the induction of connective 
tissue growth factor by transforming growth factor-  , resulting in the 
accumulation of extracellular matrix proteins. Ren and colleagues 
demonstrate that sphingosine kinase-1 is involved in the regulation of 
this pathway in the glomerulus. This raises the possibility of targeting 
sphingosine kinase-1 to prevent fibrosis in chronic kidney disease 
patients. 
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contain a complex of proteins (including 
nephrin and podocin) tethered to the 
cytoskeleton. Podocytes play a key role in 
renal fi brosis, as disruption of the slit dia-
phragm leads to the progression of albu-
minuria and depletion of podocyte 
number (a feature of glomerulosclerosis). 
In their current study, Ren  et al. 2 exam-
ine SK-1 in immortalized human podo-
cytes exposed to TGF-  . Stimulation of 
podocytes with TGF-  led to upregulation 
of SK-1 mRNA and protein levels due to 
 de novo protein synthesis, but no altera-
tion in SK-2. 2 Th is eff ect was mediated 
through TGF-  2 receptor type I and could 
not be prevented by blockers of mitogen-
activated protein kinases, protein kinase 
C, or c-Jun N-terminal kinases but was 
attenuated by Smad4 small interfering 
RNA. TGF-  also elevated CTGF expres-
sion in podocytes. Th e increase in CTGF 
could be suppressed by overexpression of 
SK-1 or augmented by inhibition of SK-1 
using either pharmacological agents or 
small interfering RNA. Th ese data suggest 
that SK-1 may be an important mediator 
of the TGF-  – CTGF axis in human 
podocytes. 
 Importantly, the authors looked at the 
relevance of their fi ndings  in vivo using 
samples from patients and animals with 
diabetic nephropathy. Diabetes leads to 
ultrastructural alterations in the glomeru-
lar  fi ltration barrier, including foot pro-
cess fusion and detachment, basement 
membrane thickening, mesangial extra-
cellular matrix accumulation, and glomer-
ulosclerosis. Immunohistochemistry in 
both patients and animals with diabetic 
nephropathy demonstrated upregulation 
of both SK-1 and CTGF in podocytes 
compared with control samples. 2 Th ese 
data concur with the observations of 
Geoff roy  et al. , who examined sphingo-
sine signaling in diabetic rats. 5 Aft er only 
four days of diabetes, they reported a 14-
fold increase in sphingosine-1-phosphate 
levels in glomeruli along with an elevation 
in SK-1 activity, which was associated 
with cell proliferation. 5 Ren  et al. 2 took 
these descriptive studies a step further by 
 comparing wild-type mice with SK-1 
knockout mice induced to become 
diabetic with streptozotocin. Intriguingly, 
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mesangial cells. 7 In these experiments, 
sphingosine-1-phosphate induced the 
phosphorylation of Smads and mimicked 
TGF-  actions such as inhibition of 
induced expression of inducible nitric 
oxide synthases, secreted phospholipase 
A 2 , and matrix metalloproteinase-9, as 
well as stimulating CTGF. In addition, 
sphingosine-1-phosphate has been shown 
to stimulate the proliferation of mesangial 
cells, 8 which is a key step in the initiation 
of glomerulosclerosis. Th e eff ect of sphin-
gosine-1-phosphate directly on glomeru-
lar endothelial cells has yet to be studied. 
However, insights have been provided 
with the use of other endothelial cells 
exposed to exogenous sphingosine-1-
phosphate. Th is action has been shown to 
alter angiogenesis and the expression of 
mediators involved in the maintenance of 
vascular tone such as nitric oxide, 9 which 
contribute to the progression of renal 
fi brosis. Th is cross-talk between the dif-
ferent glomerular cellular components 
could be further investigated with the use 
of transgenic mice with targeted dysregu-
lation of SK-1 in podocytes; similarly, 
podocyte knockout and overexpression 
strategies have been successfully used for 
vascular endothelial growth factor and 
angiopoietin-2. 10,11 A detailed analysis 
of SK-1 in all glomerular components 
in normal and disease situations would 
also be helpful. 
 In conclusion, these fi ndings raise the 
possibility that SK-1 could be a novel 
therapeutic target with which to modulate 
renal fibrosis in glomerular diseases. 
However, because of its diverse actions, 
detailed  in vivo studies are required to 
understand the interplay of intracellular 
and extracellular sphingosine-1-phos-
phate in the diff erent cell types of the renal 
glomerulus. 
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SK-1 knockout animals demonstrated 
elevated albumin / creatinine levels along-
side increased mRNA levels of glomerular 
CTGF as compared with wild-type mice. 2 
Th ese data raise the tantalizing prospect 
that modulation of SK-1 may slow the pro-
gression of diabetic nephropathy. It would 
be of considerable interest to examine the 
eff ects of SK-1 inhibition in a model of 
long-term diabetes (the mice in this study 
were studied for only 30 days), as well as 
investigate the detailed changes in glome-
rular ultrastructure in these animals. A 
rapid increase in SK-1 levels in these 
two studies of diabetic animals raises the 
possibility that factors involved in the ini-
tiation of diabetes other than TGF-  may 
be involved in altering SK-1 expression, 
such as elevated glucose levels, increased 
angiotensin II, or mechanical stretch. 6 
 It is possible that pharmacological 
agents altering SK-1 enzyme activity 
could modulate fi brosis in glomerular 
disease. On the basis of the data outlined 
above, one could postulate that therapeu-
tic agents that enhance SK-1 activity 
could attenuate fi brosis, while inhibitors 
may enhance glomerular injury. However, 
when modulation of SK-1 activity is 
considered as a therapeutic tool, compli-
cations may arise, as sphingosine-1-
phosphate has many diverse eff ects due to 
its intracellular and extracellular signal-
ing properties ( Figure 1 ). Th is issue is 
highlighted in the study by Ren and 
colleagues. 2 Initially, they hypothesize 
that as overexpression of SK-1 attenuated 
CTGF expression in podocytes, stimula-
tion of these cells with exogenous sphin-
gosine-1-phosphate would lead to similar 
eff ects. However, this regimen stimulated 
CTGF expression. 2 Th e authors teased 
out the diff erences between extracellular 
and intracellular sphingosine signaling in 
podocytes by taking an approach using 
caged sphingosine-1-phosphate. Caged 
sphingosine-1-phosphate does not bind 
to the sphingosine-1-phosphate receptors 
on podocytes but penetrates the cells 
and generates sphingosine-1-phosphate 
in the cytoplasm. When this substrate was 
used to stimulate podocytes, it reduced 
CTGF expression. 2 
 Th e overall response of the sphingo-
sine pathway to TGF-  or other stimuli 
will therefore be determined by the 
balance of intracellular and extracellular 
actions of sphingosine-1-phosphate 
 ( Figure 1 ). As sphingosine-1-phosphate 
receptors are widely expressed, the 
elevated extracellular sphingosine-1-
 phosphate produced by podocytes 
aft er TGF-  stimulation will not only 
lead to autocrine eff ects on podocytes 
themselves and increased CTGF 2 but 
may also have paracrine eff ects on adja-
cent cells such as those of the mesangium 
and endothelia ( Figure 1 ). Indeed, the 
effects of exogenous sphingosine-1-
phosphate have been studied  in vitro in 
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 Figure 1  |  Intracellular and extracellular effects of increased sphingosine-1-phosphate 
levels. Elevation of TGF-  due to a renal insult such as high glucose leads to elevated levels of SK-1 
in podocytes, which converts sphingosine to sphingosine-1-phosphate (S1P). Elevated S1P has 
intracellular effects such as suppression of connective tissue growth factor (CTGF) in podocytes. In 
addition, S1P can also cause extracellular changes acting through S1P G protein-coupled receptors 
(S1PR). This mechanism can lead to autocrine effects on podocytes as well as paracrine actions on 
endothelia and mesangial cells. SK-1, sphingosine Kinase-1; TGF-  , transforming growth factor-  . 
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